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Human papillomavirus (HPV), the most common newly
acquired, sexually transmitted infection worldwide,
infects about 75% of sexually active individuals in their
lifetimes. The high-risk HPV types, the most common
of which are HPV 16 and 18, cause cervical and other
anogenital cancers, as well as some head and neck can-
cers [1]. Different HPV types are related to different
lesion grades. HPV16 is found in about half of cervical
cancers, the majority of anal cancers and about 30% of
oropharyngeal cancers, besides a significant proportion
of vulvar, vaginal and penile carcinomas. The low-risk
types, the most common of which are HPV 6 and 11,
cause genital warts, low-grade cervical dysplasias and
recurrent respiratory papillomatosis. Most of our under-
standing of HPV and carcinogenesis is derived from stu-
dies of women and cervical cancer. However, it is clear
that HPV causes a significant proportion of tumors in
both women and men [2]. Therefore, new prophylactic
HPV vaccines have the power to prevent many HPV
infections, thus reducing the burden of HPV-associated
diseases.
Two vaccines have been developed, a quadrivalent vac-
cine that protects against HPV 16, 18, 6 and 11 (Merck &
Co., USA) and a bivalent vaccine that protects against
HPV 16 and 18 (Glaxo Smith-Kline, Belgium). Both vac-
cines are composed of HPV L1 proteins that have sponta-
neously self-assembled into virus-like particles (VLPs).
However, they have different manufacturers, valencies,
adjuvants and are produced in different types of cells.
Both are administered by intramuscular injection, in three
doses (0, 1 or 2 and 6 months). In a number of clinical
trials conducted in thousands of subjects in many coun-
tries since 1998, the safety, immunogenicity and efficacy of
these HPV VLP vaccines have been demonstrated [3].
Prophylactic efficacy was measured considering HPV
infection and disease endpoints, particularly high-grade
cervical intraepithelial neoplasia or worse for the biva-
lent and quadrivalent vaccines, as well as vulvar
intraepithelial neoplasia (VIN) or vaginal intraepithelial
neoplasia and genital warts, for the quadrivalent vaccine
only. For both the bivalent and quadrivalent vaccines,
results of different trials allow for the examination of
broad trends in efficacy in preventing HPV 6/11/16/18-
related disease in several groups of patients categorized
according to their HPV status at baseline. Very high effi-
cacy rates were observed in naive women for the vaccine-
HPV types which led to the recommendation of the vac-
cine to young individuals, prior to exposure to HPV
which occurs concomitant to sexual activity onset. Cross-
protection against non-vaccine types was also noted, but
the significance and durability of protection is yet to be
defined. To increase the coverage to more than 70% of
cervical cancers attributable to HPV 16 and 18, it is pos-
sible that the best and most efficient responses will be
obtained with multivalent vaccines against a larger num-
ber of genital, anal and oropharyngeal HPV infections
which are presently under development [4].
VLPs are noninfectious protein subunit vaccines and
show safety profiles similar to other protein subunit vac-
cines such as tetanus or hepatitis B vaccines. Both vac-
cines were generally well tolerated in clinical trials and
maintain a good safety profile after licensure. Since the
VLP vaccines were designed primarily to protect by indu-
cing virion neutralizing antibodies, type specific antibody
responses to the VLPs have been the primary focus of
immunogenicity studies. Both vaccines were shown to be
highly immunogenic in the clinical trials, resulting in
essentially 100% seroconversion in the different popula-
tions studied which included both females and males.
Both vaccines induce the expected B cell memory
response which is a property of vaccines with durable
immune responses. Although the long term persistence
of stable antibody levels is an encouraging finding, the
antibody levels needed to prevent infection or disease are
currently unknown. However, long-term follow-up stu-
dies have shown that efficacy is maintained for at least
ten years and modeling studies suggest protection may
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last much longer. Available data do suggest that HPV
vaccines may provide a lengthy period of protection,
likely to usher a vaccinated individual through the years
of highest infection risk and beyond. Additional studies
are ongoing to verify these projections.
HPV vaccines introduction and implementation. Based
on its demonstrated clinical efficacy and favorable safety
profile, HPV prophylactic vaccines have been introduced
in hundreds of countries around the world, including
most countries in Latin America. In Brazil, the quadriva-
lent HPV vaccine was approved in 2006 and the bivalent
vaccine in 2008 [5]. The rapid approval and launch of
such vaccines are a clear indication that governments
and policy makers are aware of the expected impact on
the prevention of one of the most common causes of
female mortality worldwide.
In 2007, Australia was one of the first countries to
introduce the quadrivalent HPV vaccine in a public
immunization programme for girls and young women.
Four years after the beginning of the HPV vaccination
program, a substantial decrease in vaccine-targeted gen-
otypes is evident. In fact, a dramatic reduction in genital
warts was observed in young women as well as young
men, an indication of herd immunity [6]. On the other
hand, older women and men, as well as men who have
sex with men, show very little or no reduction of this
benign tumor caused by low-risk HPV types. These
results led Australia to include young men in their
national immunization program which, in time, translate
into reductions in HPV-related lesions in both genders.
Moreover, a reduction in high-grade cervical abnormal-
ities is being observed as a consequence of the introduc-
tion of HPV vaccination [7]. Similar results are rapidly
accumulating in several countries which implemented
national HPV vaccination programs including New Zeal-
and, Sweden, Denmark, Belgium, Germany, Canada, and
USA. Despite such very positive results, incorporation of
HPV vaccination in the public health sector is still to be
seen in the developing world, mostly due to vaccine
cost. HPV vaccine implementation will also depend on
local infrastructure for vaccine delivery to the initial tar-
get population during the window of highest vaccine
efficacy, i.e., prior to sexual exposure. Furthermore,
introducing HPV vaccines in the present cervical cancer
control system is hampered by the fact that secondary
screening with Pap tests (or HPV DNA testing) will still
be required to detect cervical cancers and pre-cancers
caused by non-vaccine HPV types [8]. Ongoing cost-
benefit studies and negotiations between governments,
the private sector, and non-governmental organizations,
are enabling several developing countries, where the
vaccine is most needed, to implement the necessary pro-
grams [9]. The Ministry of Health of Brazil has
announced in June 2013 the decision to introduce the
quadrivalent HPV vaccine in the national immunization
program. From 2014, this vaccine will be offered to girls
and adolescents 11-12 years old. The details of the pro-
gram are largely unknown which includes the possibility
of an extended vaccination schedule (0, 6, 60 months; in
clinical trials 0, 2 6 months).
The success of the prophylactic vaccines against HPV
is clear. However, these vaccines are not and will not be
available in the short run, as public immunization pro-
gram in many countries. Moreover, the coverage rates
will vary at large due to economic restrictions and other
issues. Vaccine acceptance is largely de-termined by
health beliefs, such as the individual’s perceived suscept-
ibility to the disease, vaccine characteristics, such as cost
and efficacy, and obstacles to obtaining the vaccine.
Education of physicians, policy makers, parents and ado-
lescents will be crucial for delivering HPV vaccines to
target populations during the window of highest vaccine
efficacy, prior to sexual debut. Despite all efforts and the
excellent results observed in real life, it may take some
time before these vaccines are administered to the gen-
eral population worldwide. Moreover, women will still
be at risk for developing cancers caused by other HPV
types not included in the vaccine and hence screening
and monitoring strategies will be required. It is impor-
tant to stress that disease outcomes should be recorded
since at present there is no immune correlate and the
importance of serum antibody levels is simply not
known. Moreover, vaccinated populations should be fol-
lowed-up for long-term safety, sustained immune
responses and vaccine disease efficacy [10].
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